NASDAQ:LPTX - Leap Therapeutics Stock Price, Forecast & News

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Leap Therapeutics Inc (NASDAQ:LPTX) announced its quarterly earnings data on Thursday, November, 14th. The company reported ($0.33) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.33). View Leap Therapeutics' Earnings History.

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Leap Therapeutics.

2 analysts have issued 1-year price targets for Leap Therapeutics' stock. Their forecasts range from $2.50 to $3.25. On average, they anticipate Leap Therapeutics' share price to reach $2.88 in the next year. This suggests a possible upside of 61.5% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.

News stories about LPTX stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Leap Therapeutics earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Leap Therapeutics.

Leap Therapeutics saw a decrease in short interest in December. As of December 13th, there was short interest totalling 924,800 shares, a decrease of 10.2% from the November 28th total of 1,030,000 shares. Based on an average trading volume of 178,800 shares, the short-interest ratio is presently 5.2 days. Currently, 6.4% of the shares of the stock are sold short. View Leap Therapeutics' Current Options Chain.

Some companies that are related to Leap Therapeutics include Galectin Therapeutics (GALT), Akorn (AKRX), Spero Therapeutics (SPRO), TAIWAN LIPOSOME/S (TLC), Corvus Pharmaceuticals (CRVS), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), CannTrust (CTST), Adamas Pharmaceuticals (ADMS), Menlo Therapeutics (MNLO), Selecta Biosciences (SELB), ContraFect (CFRX), Sierra Oncology (SRRA), Savara (SVRA) and AcelRx Pharmaceuticals (ACRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Baidu (BIDU) and Fate Therapeutics (FATE).

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LPTX stock can currently be purchased for approximately $1.78.

Leap Therapeutics has a market capitalization of $43.07 million. The company earns $-23,140,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.View Additional Information About Leap Therapeutics.

The official website for Leap Therapeutics is http://www.leaptx.com/.

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.